Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Leases (2019 - 2025)

Anika Therapeutics (ANIK) has disclosed Current Leases for 7 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 6.99% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 6.99% increase, with the full-year FY2025 number at $2.1 million, up 6.99% from a year prior.
  • Current Leases was $2.1 million for Q4 2025 at Anika Therapeutics, up from $1.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.3 million in Q3 2024 to a low of $119000.0 in Q1 2021.
  • A 5-year average of $1.6 million and a median of $1.9 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 86.92% in 2021, then surged 1625.41% in 2023.
  • Anika Therapeutics' Current Leases stood at $188000.0 in 2021, then surged by 1002.66% to $2.1 million in 2022, then decreased by 11.87% to $1.8 million in 2023, then grew by 4.98% to $1.9 million in 2024, then increased by 6.99% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Current Leases are $2.1 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025).